Pacific Time (GMT-8)

Central (GMT-6)

Eastern (GMT-5)

London (GMT)

8 AM-10:30 AM

10 AM-12:30 PM

11 AM-1:30 PM

4 PM- 6:30 PM

2021 AGENDA (Times Listed in PacificTime)***Subject to Change***

Event Chair:   Ibiayi Dagogo-Jack MD      Event Co-Chair: H. Jack West MD

Panel Guests: Drs. Estelamari Rodriguez, Riyaz Shah, Narjust Duma,

Melina Marmarelis, Adrian Sacher, and Aparna Hegde 

Register at https://us02web.zoom.us/webinar/register/WN_nwlz5P5bSOCSZ9L3Whl3cQ

8:00 AM

Welcome and Opening Remarks

Event Chair: Ibiayi Dagogo-Jack MD,  Event Co-Chair: H. Jack West

8:05-9:00

Panel 1:  H. Jack West MD with Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma

Early Stage NSCLC

  • Molecular Testing
  • Testing in potentially resectable NSCLC and unresectable locally advanced NSCLC?
  • Differences by histology and/or smoking status?
  • Patient with Resectable NSCLC and EGFR Mutation
  • Recommendations depending on stage?
  • Anticipated Surgery
  • Does the extent of anticipated surgery alter recommendations, specifically the potential need for pneumonectomy?
  • Neoadjuvant Therapy vs. Adjuvant Therapy
  • Where does it fit in now?
  • Where does it fit in the future?
  • The Role of Circulating Tumor DNA for Minimal Residual Disease Today
  • Should We Extrapolate Across Molecular Markers in the Curative Setting?
  • Should We Incorporate the Rationale From Data in Advanced NSCLC to Early Stage NSCLC?
  • What Factors Should Be Considered as We Think About Whether to Adopt a New Intervention Based on a Surrogate Endpoint?

9:05-10:00

Panel 2: Ibiayi Dagogo-Jack MD with Drs. Melina Marmarelis, Adrian Sacher, and Aparna Hegde

Advanced NSCLC

  • Is Broad NGS Sequencing the Clear Standard Of Care for Molecular Testing Today?
  • Does it apply to squamous NSCLC?
  • What are the leading barriers to seeing this practiced in the community setting?
  • How much can liquid biopsy shore up this gap?
  • How can we improve testing?
  • Optimal Timing of KRAS Inhibitor Therapy
  • Patient Whose Tumor is Squamous and High Tumor PD-L1
  • Should we consider foregoing WBRT for brain metastases?
  • New Patient Case
  • Squamous NSCLC, PD-L1 60%, >10 small, asymptomatic brain metastases
  • Patients with high PD-L1 NSCLC
  • Which should receive chemo with immunotherapy?
  • What is the Place of Immunotherapy Doublets vs. Other Options
  • Specific Considerations for Patients with Tumor PD-L1 <1%
  • Management of Patients With a Driver Mutation Following Acquired Resistance on Targeted Therapy (Once Targeted Therapies are Exhausted)
  • Timing of immunotherapy (if ever)?
  • Does history of brain metastases matter?
  • Use of ctDNA
  • For early assessment of response vs. possible progressing disease?

10:05-10:20

Q&A

10:25 AM

Closing Remarks Event Chair: Ibiayi Dagogo-Jack MD